Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Acumapimod (BCT-197) 是一种有口服活性的p38 MAP 激酶抑制剂,IC50值小于1 μM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 348 | 现货 | ||
2 mg | ¥ 491 | 现货 | ||
5 mg | ¥ 798 | 现货 | ||
10 mg | ¥ 1,220 | 现货 | ||
25 mg | ¥ 1,980 | 现货 | ||
50 mg | ¥ 3,690 | 现货 | ||
100 mg | ¥ 5,320 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 913 | 现货 |
产品描述 | Acumapimod (BCT-197) is an orally active inhibitor of p38α MAPK (IC50 <1 μM). |
靶点活性 | p38α:<1 μM |
体内活性 | Acumapimod increases survival and reduces the number of macrophages in bronchoalveolar lavage fluid (BALF) in a mouse model of infection with influenza H1N1 A/PR/8/34 when administered at a dose of 6 mg/kg[1] |
动物实验 | In vivo, female BALB/c mice were infected intranasally with 150 pfu of influenza H1N1 A/Puerto Rico/8/34 and treated with Acumapimod(BCT197) (a closely related p38 MAPK inhibitor with an IC50 value of<1?μM, currently in clinical testing), dexamethasone or oseltamivir (Tamiflu) starting 24?h post infection. Body weight, bronchoalveolar lavage cells, cytokines, total protein and lactate dehydrogenase as well as serum cytokines were measured; a subset of animals was evaluated histopathologically[1]. |
别名 | BCT-197 |
分子量 | 385.42 |
分子式 | C22H19N5O2 |
CAS No. | 836683-15-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (129.73 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.5946 mL | 12.9729 mL | 25.9457 mL | 64.8643 mL |
5 mM | 0.5189 mL | 2.5946 mL | 5.1891 mL | 12.9729 mL | |
10 mM | 0.2595 mL | 1.2973 mL | 2.5946 mL | 6.4864 mL | |
20 mM | 0.1297 mL | 0.6486 mL | 1.2973 mL | 3.2432 mL | |
50 mM | 0.0519 mL | 0.2595 mL | 0.5189 mL | 1.2973 mL | |
100 mM | 0.0259 mL | 0.1297 mL | 0.2595 mL | 0.6486 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Acumapimod 836683-15-9 Autophagy MAPK p38 MAPK inhibit BCT197 Inhibitor BCT-197 BCT 197 inhibitor